[author: Sherri Oslick]
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Eisai R & D Management Co., Ltd. v. Honorable David J. Kappos
1:12-cv-01138; filed October 12, 2012 in the Eastern District of Virginia
Review and correction of the patent term adjustment calculation made by the U.S. Patent and Trademark Office for U.S. Patent No. 8,158,620 ("Fused Aminodihydrothiazine Derivatives," issued April 17, 2012). View the complaint here.
Genetic Technologies Ltd. v. Genetics & IVF Institute, Inc.
3:12-cv-00724; filed October 11, 2012 in the Eastern District of Virginia
Infringement of U.S. Patent No. 5,612,179 ("Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes," issued March 18, 1997) based on Genetics & IVF Institute's manufacture, use, sale, and offer for sale of preimplantation genetic diagnosis services. View the complaint here.
Purdue Pharma LP et al. v. Sandoz Inc.
1:12-cv-07582; filed October 10, 2012 in the Southern District of New York
• Plaintiffs: Purdue Pharma LP; Grunenthal GmbH
• Defendant: Sandoz Inc.
Infringement of U.S. Patent No. 8,114,383 ("Abuse-Proofed Dosage Form," issued February 14, 2012 following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint here.